FAQ North America
Gilead has an internal review committee that reviews and awards grants based on how closely the proposed project matches the company’s mission and therapeutic focus areas.
Gilead doesn’t place a limit on how much grantees can apply for. We want you to request the level of funding that you’ll need to make your project a success.
No, only tax exempt nonprofits are eligible.
Gilead does not provide retroactive funding. Requests for support must be submitted to us at least 6 weeks prior to the start of the activity.
Absolutely. However, to ensure Gilead can support a wide variety of projects, we don’t consider repeat grant requests for the same project made within the same 12-month period.
There's no need. Gilead keeps it simple by having all funding requests — even for projects occurring on multiple dates or in multiple locations — submitted as a single, comprehensive application.
Please submit your application under the therapeutic area to which your project is most closely aligned. Then, in your application, describe your project objectives for each therapeutic area covered.
No, we will only consider grant applications that contain a detailed project budget breaking down how you will use the funds requested from Gilead.
The online form allows you to upload a project budget and event agenda. To include additional files, please email them to firstname.lastname@example.org after submitting the online application form. (Be sure to indicate your organization name and tax ID number, project title and Gilead Grant ID number.)
We do not. If grant funding is approved, you may submit your own LOA template, complete with the details of the funded activity (amount funded, date of project, program location, etc.) and Gilead Grant ID number, to email@example.com. It will take us about 2 weeks to process and return it to you.
Gilead sends notification of the funding decision on each application by email directly to the contact listed on the Gilead grant account profile.
Under Section 6002 of the Patient Protection and Affordable Care Act (also known as “OPEN PAYMENTS” or the “Physician Payments Sunshine Act”), all drug and device manufacturers are required to report to the Centers for Medicare & Medicaid Services (CMS) information concerning payments made to physicians and teaching hospitals on an annual basis, and CMS will make the details available for public viewing on its website. This may result in public disclosure of the following:
- Grant payments Gilead makes to teaching hospitals (as defined by CMS)
- Grant payments Gilead makes that grantees use to fund payments or other transfers of value to U.S. physicians (defined as an M.D., D.O., podiatrist, optometrist, licensed chiropractor, dentist or dental surgeon)
You can learn more about this requirement here.
Yes, if you need technical assistance with Gilead’s grants portal. But keep in mind representatives cannot comment on the decision process related to specific grant requests.
For information about Gilead funding opportunities for programs that span multiple countries within Europe, Australia and the Middle East, please submit an inquiry to EMEAgrants@gilead.com. For country-level programs within these regions, please contact the local Gilead office.
For all other regions outside the United States, please email firstname.lastname@example.org and we will be happy to point you in the right direction.